References
1) Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun 2020;109:102433,2.
2)Zhang P, Zhu L, Cai J, Lei F, Qin JJ, Xie J,et al. Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res 2020.
3) Sommerstein R, Kochen MM, Messerli FH, Gra¨ni C. Coronavirus disease 2019 (COVID-19): do angiotensin-converting enzyme inhibitors/angiotensin receptor blockers have a biphasic effect. J Am Heart Assoc 2020;9:e016509.
4)Reynolds HR, Adhikari S, Pulgarin C, et al. Renin–angiotensin–aldosterone system inhibitors and risk of Covid-19. N Engl J Med. DOI: 10.1056/NEJMoa2008975.
5) Morrow DA, Velazquez EJ, DeVore AD, Desai AS, Duffy CI, Ambrosy AP, Gurmu Y, McCague K, Rocha R, Braunwald E. Clinical outcomes in patients with acute decompensated heart failure randomly assigned to sacubitril/valsartan or enalapril in the PIONEER-HF Trial. Circulation 2019;139: 2285–2288.
6) Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, Gong W, Liu X, Liang J, Zhao Q, Huang H, Yang B, Huang C. Association of cardiac injury with mortality in hospital patients with COVID-19 in Wuhan, China. JAMA Cardiol 2020;doi:10.1001/jamacardio. 2020.0950.
7) Gao L, Jiang D, Wen XS, Cheng XC, Sun M, He B, You LN, Lei P, Tan XW, Qin S, Cai GQ, Zhang DY. Prognostic value of NT-proBNP in patients with severe COVID-19. Respir Res 2020; 21:83..
8) Li N, Zhang Y, Fan S, Xing J, Liu H BNP and NT-pro BNP levels in patients with sepsis Front Biosci (Landmark Ed). 2013;18:1237-43.
9) Jensen J, Ma LP, Fu ML, Svaninger D, Lundberg PA, Hammarsten O. Inflammation increases NT-proBNP and NT-pro BNP/BNP ratio Clin Res Cardiol. 2010;99(7):445-52. doi: 10.1007/s00392-010-0140-z. Epub 2010 Mar 13.
10) Singh JSS, Burrell LM, Cherif M, Squire IB, Clark AL, Lang CC. Sacubitril/valsartan:beyond natriuretic peptide Heart. 2017;103(20):1569-1577.
11) L. Mezzasoma, C. Antognelli,and V. Talesa Novel Role for Brain Natriuretic Peptide: Inhibition of IL-1𝛽 Secretion via Downregulation of NF-kB/Erk 1/2 and NALP3/ASC/Caspase-1 Activation in Human THP-1 Monocyte Mediators of Inflammation. 2017.